Close Menu

NEW YORK – Proteomics firm Seer on Thursday evening priced its initial public offering of 9,210,527 shares of common stock at $19 per share for anticipated gross proceeds of $175 million.

Shares of the Redwood City, California-based company will begin trading Friday on the Nasdaq under ticker symbol SEER.

Seer is also granting the IPO underwriters a 30-day option to purchase up to an additional 1,381,579 shares of Class A common stock at the initial public offering price, less the underwriting discounts and commissions.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.

Apr
20
Sponsored by
Olink

This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.

Apr
23
Sponsored by
Isoplexis

Recent advances in single-cell technologies have provided unprecedented -omic-level insights into cellular heterogeneity and function. 

May
10
Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
20
Sponsored by
ACD

This webinar will present a research project that is using spatial transcriptomics to discern the molecular mechanisms underlying fear memory.